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Introduction: The number of people with diabetes in
Africa is projected to increase substantially in the next
two decades, due to factors including rapid
urbanisation, adoption of unhealthy diets and exercise
patterns and the ageing of the population. There are
currently uncertainties regarding the incidence,
prevalence and management patterns of diabetes in
older people across the diversity of African countries.
We wish to perform a systematic review to determine
the prevalence of type 2 diabetes in Africa in the older
individual, over the age of 55 years, reported in studies
from 2000 to 2013.
Methods and analyses: A comprehensive literature
search among a number of databases will be
undertaken, using an African search filter to identify
diabetes prevalence studies that were published from
2000 to 2013. Full copies of articles identified by the
search, and considered to meet the inclusion criteria,
will be obtained for data extraction and synthesis.
Statistical analysis of the primary measures, fasting
plasma glucose (FPG) and oral glucose tolerance test
will include two steps: (1) identification of data sources
and documenting estimates and (2) application of the
random-effects meta-analysis model to aggregate
prevalence estimates and account for between study
variability in calculating the overall pooled estimates
and 95% CI for diabetes prevalence. Heterogeneity will
be evaluated using the I2 statistic to determine the
extent of variation in effect estimates that is due to
heterogeneity rather than chance. This systematic
review will be reported according to the Preferred
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA).
Ethics and dissemination: Ethics is not required for
this study, given that this is a protocol for a systematic
review, which utilises published data. The findings of
this study will be widely disseminated through peer-
reviewed publications and conference presentations.
INTRODUCTION
The most recent International Diabetes
Federation (IDF) estimates from 2013 are
that 8.3% of adults that is, 382 million
people worldwide have diabetes. This
number has doubled over the past 20 years,
and notably 80% of people with diabetes live
in low and middle income countries
(LMIC).1 Diabetes already contributes sig-
niﬁcantly to morbidity and mortality in
Africa. The highest global age-speciﬁc mor-
tality rate is recorded in this continent.2–6 All
countries in Africa fall into the LMIC cat-
egory, and predominantly the low income
category. The rise in the number of indivi-
duals with type 2 diabetes in Africa, similar
to LMIC has been attributed to ageing of the
population and relatively rapidly changing
environmental factors.1 These include urban-
isation, the adoption of health behaviours
favouring sedentariness and unhealthy eating
patterns. While unhealthy behaviour patterns
and obesity are potentially modiﬁable, ageing,
one of the major drivers for diabetes, is not.7
In 2013, the majority of individuals with dia-
betes in Africa were reported to be under
60 years of age with the highest proportion
(43.2%) in people aged 40–59 years.7 The
relatively small proportion of individuals aged
60–79 years in the region is likely to account
for the estimate that only 18.8% of patients
with diabetes fall in this age group.1
Africa is often referred to as the youngest
continent in terms of age structure. This may
contribute to the current relatively low priori-
tisation of ageing issues in national policies.8
Yet the annual growth rate of older persons
in Africa has been estimated at 3.1%
between 2007 and 2015, and 3.3% between
2015 and 2050, greater than the global
average. In this context, it is concerning that
there will be approximately 64.5 million
Africans aged ≥55 years in 2015, and more
than 103 million and 205 million in 2030
and 2050, respectively.6 Indeed it has been
predicted that the diabetes peak in Africa is
expected to be in the oldest individual by
2035.1 We therefore wish to perform a
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systematic review to determine the prevalence of type 2
diabetes in Africa in older individuals over the age of
55 years, reported in studies from 2000 to 2013 with a
view to providing accurate data for monitoring future
trends. The data will also be of value in informing
health policy makers of the extent of the burden of dia-
betes in an under researched group whose healthcare
needs may differ from those in younger adults.
OBJECTIVES
To conduct a systematic review and meta-analysis of
studies assessing the prevalence of type 2 diabetes
among older people in African countries.
Review question
This systematic review will be guided by the following
research question:
What is the prevalence of type 2 diabetes in older
persons aged 55 years and older in African countries as
reported in studies from 2000 to 2013?
Criteria for considering studies for review
Inclusion criteria
1. Studies describing the prevalence of type 2 diabetes
among older adults, resident in countries belonging
to the African continent, in the geographic regions
of sub-Saharan and North Africa diagnosed with type
2 diabetes from all ethnicities, socioeconomic and
educational backgrounds. Participants should be
described as older adults or a minimum of 70% of
participants should be within the age groups of
55–64, 65–74 or 75+ years.
2. Population-based studies, cross-sectional studies of
type 2 diabetes. For the purpose of this review, the
diagnosis of diabetes should be made by a physician
or deﬁned by available measured fasting plasma
glucose (FPG), oral glucose tolerance test (OGTT)
or self-reported, according to WHO criteria.9
We will consider published articles and unpublished
studies reported after 1 January 2000, given that the
current criteria for the diagnosis of diabetes have been
widely accepted since 1998. Articles published in any
language, with full English abstracts will be eligible for
inclusion.
Exclusion criteria
1. Studies which include a mixed group of type 1 and
type 2 participants, or that do not clearly deﬁne the
type of diabetes as being type 2, will be excluded.
2. Studies conﬁned to subgroups of patients with type 2
diabetes (with any complication of diabetes mellitus
(DM) eg: myocardial infarction, eye, kidney or other
microvascular or macrovascular complications).
3. Studies that do not include a representative sample
of older people aged 55 years or older.
4. Narrative reviews, opinion pieces, letters or any other
publications lacking primary data and/or explicit
method descriptions.
5. Duplicate publications of the same material. When
the study has been published in more than one
journal/conference; the most complete recent
version will be used.
6. The studies that had low-quality scores (equal to or
below 5) in the assessment of risk of bias.
Search strategy for identification of relevant studies
The search strategy will comprise two stages:
Bibliographic databases
A. A comprehensive and sensitive search strategy will be
undertaken using an African search ﬁlter developed
by Siegfried10 to identify prevalence studies con-
ducted from 2000 to the African ﬁlter comprising
country names from the continent as well as trun-
cated terms such as ‘north* Africa’ to ensure that
records indexed using regional, rather than country-
speciﬁc, terms are also retrieved. Database subject
headings (MeSH in PubMed/MEDLINE, CINHAL
and Google Scholar) will be combined with a range
of text words (see online supplementary appendix
1). African country names are included in English
and languages relevant to the country, for example,
‘Ivory Coast’ and ‘Cote d‘Ivoire’. Where country
names have changed over time both names are
included, for example, ‘Democratic Republic of
Congo ’and ‘Zaire’.11
B. Publications of identiﬁed key authors will be exam-
ined by citation searches on the IDF and WHO web-
sites for example, STEPS surveys studies in Africa as
well as on the ISI Web of Knowledge platform. A bib-
liographic software programme for managing the
references and documenting the study selection
process will be used for this review. An expert librarian
will help in designing the search strategy framework
and implementing the appropriate bibliographic soft-
ware programme (for the detailed search strategy, see
online supplementary appendix 2.)
Selecting studies for inclusion
Full copies of articles identiﬁed by the search, and con-
sidered to meet the inclusion criteria, based on the title
and abstract will be obtained for data synthesis. Initially,
studies will be screened using predeﬁned inclusion and
exclusion criteria. Two reviewers will apply the criteria
independently to the results of the searches, based ﬁrst
on titles and abstracts only. Studies will then be either
(1) excluded, (2) included or (3) marked as ‘pending’
if the reviewer is unsure about their inclusion. The two
independent reviews will be compared and contradictory
judgments or ‘pending’ will be temporarily ‘included’,
and moved to the next phase of review of full texts.
Once full texts have been retrieved, two reviewers will
independently apply inclusion and exclusion criteria,
based on quick assessments of the full texts.
Disagreements in reviewer selections will be resolved at a
meeting between reviewers prior to selected articles
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being retrieved. A ﬂow chart will be produced to facili-
tate transparency of the process.
Quality appraisal of included studies
A quality assessment tool, based on guidelines for evalu-
ating prevalence studies as suggested by Hoy et al12 has
been developed (table 1). This will be applied to
screened full-text articles in order to code eligibility
decisions and to assess study quality and agreement
between investigators. Assessment of bias is built into the
quality scoring scale. We plan to evaluate risk of selec-
tion and attrition bias using the Cochrane guidelines as
set out in Review Manager V.5.2 (http://ims.cochrane.
org/RevMan). This will inform the feasibility of and
selection of studies for a pooled analysis. Any disagree-
ments will be resolved by discussion and consensus in
consultation with the third author to resolve persistent
inconsistencies.
Data extraction and management
Following assessment of methodological quality, two
reviewers will extract data onto a purpose-designed data
extraction form and independently summarise what they
consider to be the most important results from each
study. These summaries will be compared and any differ-
ences of opinion will be resolved by discussion and con-
sultation with a third reviewer. Any further calculations
on study data considered necessary, will be conducted by
the ﬁrst reviewer and checked by the second reviewer.
Study characteristics including country where study was
conducted, year of publication, journal, language of
publication, study population, age range, response rate,
study design, criteria for sample selection and sample
size, outcome(s) measured, diagnostic criteria, results
and notes/comments will be presented in tables (see
online supplementary appendix 3). We are anticipating
that some eligible studies will not have prevalence data
reported for the speciﬁc age range (ie, ≥55 years). We
will contact the corresponding authors of these studies
and request the age-speciﬁc prevalence and any other
missing information, deemed to be relevant.
Data synthesis including assessment of heterogeneity
Our statistical analysis of the primary measures, FPG and
OGTT will include two steps: (1) identiﬁcation of data
sources and documenting estimates and (2) application
of the random-effects meta-analysis model to aggregate
prevalence estimates and account for between study vari-
ability in calculating the overall pooled estimates and
95% CI for diabetes prevalence. We will derive SEs
where studies have provided the corresponding numer-
ator and denominator for diabetes prevalence estimates.
We will consider non-overlapping CIs as an indication of
statistically signiﬁcant differences. Prevalence of type 2
DM from different studies will be pooled in a
meta-analysis using (STATA V.12 statistical software).
Heterogeneity will be assessed by inspecting forest plots
initially, then through the Cochran’s χ2 test using a 10%
level of signiﬁcance cut-off (due to the low power of the
test), and the I2 statistic where values of 25%, 50% and
75% reﬂect low, medium and high heterogeneity,
respectively.13 Where heterogeneity is statistically signiﬁ-
cant, subgroup analysis, using the following variables:
age group, sex, setting for example, urban/rural geo-
graphical region for example, northern/southern,
western/eastern, as well as sensitivity analyses will be
conducted to determine the potential sources of
heterogeneity.
Furthermore a sensitivity analysis will be performed to
evaluate how excluding studies that did not meet each
quality criterion would affect our overall estimate.
Another sensitivity analysis will be conducted to ﬁnd out
how our results would change if only high-quality studies
were considered. If the identiﬁed studies are of substan-
tial heterogeneity and where statistical pooling is not
possible, the ﬁndings will be presented in narrative form
Table 1 Quality assessment criteria for prevalence studies12
Items Quality score
External validity
1. Was the study’s target population a close representation of the national population in relation to relevant
variables?
(1 point)
2. Was the sampling frame a true or close representation of the target population? (1 point)
3. Was some form of random selection used to select the sample, OR was a census undertaken? (1 point)
4. Was the likelihood of non-response bias minimal? (1 point)
Total (4 points)
Internal validity
1. Were data collected directly from the participants (as opposed to a proxy)? (1 point)
2. Was an acceptable case definition used in the study? (1 point)
3. Was the study instrument that measured the parameter of interest shown to have validity and reliability? (1 point)
4. Was the same mode of data collection used for all participants? (1 point) (1 point)
5. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1 point)
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point)
Total (6 points)
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including tables and ﬁgures to aid in data presentation
where appropriate. The narrative will be written by the
two reviewers and then checked independently by the
other reviewers, any disagreements will be decided by all
reviewers.
ASSESSMENT OF REPORTING BIASES
Symmetry of funnel plots will be used to assess for publi-
cation or selective reporting bias.
REPORTING OF THIS REVIEW
This systematic review will be reported according to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) Statement.13 A reporting
guideline for systematic reviews of healthcare interven-
tion will include a PRISMA checklist. Where necessary,
we will adapt the reporting to ensure that all items rele-
vant to this review are included in the report.
ETHICS AND DISSEMINATION
Given that this is a protocol for a systematic review,
which utilises published data, ethics is not required for
this study. The ﬁndings of this study will be widely disse-
minated through peer-reviewed publications, conference
presentations and submitted to relevant authorities in
national departments of health. Updates of the review
will be conducted to inform and guide healthcare
practice.
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